Piper Jaffray analyst Matt O'Brien says the recent pullback in shares of Wright Medical represents a good entry point. After hosting investor meetings with management this week, the analyst recommends buying the stock at these levels. Wright has dismissed all but one of their troubled lower extremity distributors and started selling through its own direct reps in these territories as of August 1, O'Brien tells investors in a research note. With the upper extremities business still growing quickly and a commitment to the EBITDA metrics laid out before the issue surfaced, "there is a lot to like here," says the analyst. He keeps an Overweight rating on the shares with a $27 price target.